# BCLAF1

## Overview
BCLAF1, or BCL2 associated transcription factor 1, is a gene that encodes a nuclear protein involved in various cellular processes, including apoptosis, transcription regulation, and RNA metabolism. The protein, categorized as a transcription factor, plays a crucial role in DNA repair, particularly in response to DNA damage, and is involved in the regulation of the cell cycle. BCLAF1 interacts with multiple proteins and forms complexes that are essential for its function in splicing regulation and DNA damage repair. The gene is subject to alternative splicing, resulting in different isoforms that may have distinct roles in cellular processes. BCLAF1 is implicated in several diseases, particularly cancers, where its expression levels and interactions can influence tumor progression and treatment resistance (Lee2012BCLAF1; Yu2021Function; McPherson2012BCLAF1).

## Structure
BCLAF1, also known as Bcl2-associated transcription factor 1, is a protein involved in apoptotic signaling and transcriptional repression. It contains several domains, including a basic leucine zipper (bZIP) DNA binding domain and a Myb DNA binding domain, which are crucial for its function in gene regulation (McPherson2012BCLAF1). The N-terminal region of BCLAF1 is rich in arginine and serine, forming an RS domain, which is typical of proteins involved in pre-mRNA splicing and processing (McPherson2012BCLAF1; Sarras2010In).

BCLAF1 is subject to alternative splicing, resulting in at least four isoforms. The two predominant isoforms include a longer form of 920 amino acids and a smaller form missing 49 amino acids, with molecular masses of 106 kDa and 101 kDa, respectively (McPherson2012BCLAF1). The inclusion of exon5a in the BCLAF1 transcript is tissue-specific and affects the protein isoforms produced, with the BCLAF1-L isoform being particularly implicated in colorectal tumorigenesis (Zhou2014BCLAF1).

BCLAF1 is phosphorylated, although the significance of this modification is not fully understood. It is also a target for microRNAs encoded by Kaposi's sarcoma-associated herpesvirus (KSHV) (McPherson2012BCLAF1). The protein is involved in multiple protein-protein interactions, forming complexes with proteins like SkIP, TRAP150, and Pinin, and is part of ribonucleoprotein complexes (McPherson2012BCLAF1).

## Function
BCLAF1 (BCL2 associated transcription factor 1) is a nuclear protein involved in several critical cellular processes, including apoptosis, transcription regulation, and RNA metabolism. In healthy human cells, BCLAF1 plays a significant role in the regulation of apoptosis and DNA repair, particularly in response to DNA damage such as double-strand breaks induced by ionizing radiation. It interacts with the DNA-PKcs complex, facilitating efficient DNA repair through non-homologous end joining (NHEJ) and stabilizing the Ku70/DNA-PKcs complex (Lee2012BCLAF1).

BCLAF1 is also involved in cell cycle regulation, acting as a negative regulator of p21-dependent cell cycle arrest, particularly at the G1 or S phase. It modulates the expression of cyclins such as cyclin D1 and cyclin E, influencing cell cycle dynamics and maintaining the balance between cell cycle progression and arrest (Lee2012BCLAF1).

In addition to its role in DNA repair and cell cycle regulation, BCLAF1 is implicated in RNA metabolism. It is associated with ribonucleoprotein complexes and may regulate alternative splicing, although its precise function in RNA processing remains to be fully elucidated (Sarras2010In). BCLAF1's involvement in these processes highlights its importance in maintaining genomic stability and proper cellular function.

## Clinical Significance
BCLAF1 (BCL2 associated transcription factor 1) is implicated in various diseases and conditions through mutations, expression level changes, and interaction alterations. In hepatocellular carcinoma (HCC), BCLAF1 is highly expressed and promotes cell proliferation, invasion, and drug resistance by activating the transcription of lncRNA NEAT1 and mediating the glycolytic pathway (Yu2021Function; Mou2020BCLAF1). Its overexpression is associated with higher tumor grades and lower survival rates, particularly in patients resistant to treatments like atezolizumab and bevacizumab (Yao2023BCLAF1induced).

In acute myeloid leukemia (AML), BCLAF1 expression is inversely related to miR-194-5p levels, with lower BCLAF1 expression linked to a favorable prognosis and increased sensitivity to treatment (Yu2021Function; Dell’Aversana2017miR1945pBCLAF1). BCLAF1 also plays a role in lung cancer, where it can promote tumorigenesis and resistance to cisplatin by affecting DNA damage repair (Yu2021Function).

Mutations in BCLAF1 have been observed in several cancer types, including endometrial, blood, and skin cancers, with varying mutation frequencies (Yu2021Function). These mutations and expression changes highlight BCLAF1's complex role in cancer progression and treatment resistance.

## Interactions
BCLAF1 (BCL2 associated transcription factor 1) is involved in various protein interactions, forming complexes and participating in regulatory pathways. It is a component of the SNARP complex, which includes Thrap3, SNIP1, SkIP, and Pinin, and is involved in splicing regulation and DNA damage repair (DDR) (Shcherbakova2021Identifying). BCLAF1 directly interacts with Thrap3 and Erh, forming the TEB complex, which plays a role in splicing regulation and can compensate for each other's loss, indicating partial functional redundancy (Shcherbakova2021Identifying).

BCLAF1 interacts with C/EBPβ, a transcription factor involved in the senescence-associated secretory phenotype (SASP). This interaction is mediated by the Myb domain of BCLAF1 and the leucine zipper region of C/EBPβ, and is crucial for the upregulation of C/EBPβ during DNA damage-induced senescence (Shao2016Bclaf1). BCLAF1 also forms a complex with γH2AX, stabilizing the Ku70/DNA-PKC complex to facilitate the non-homologous end joining (NHEJ) pathway of DNA double-strand break repair (Yu2021Function).

In the context of type I interferon signaling, BCLAF1 enhances the binding of the ISGF3 complex to the promoters of interferon-stimulated genes, interacting primarily through STAT2 (Qin2019Bclaf1). These interactions highlight BCLAF1's multifaceted role in cellular processes, including transcription regulation, splicing, and DNA repair.


## References


[1. (Lee2012BCLAF1) Y Y Lee, Y B Yu, H P Gunawardena, L Xie, and X Chen. Bclaf1 is a radiation-induced h2ax-interacting partner involved in γh2ax-mediated regulation of apoptosis and dna repair. Cell Death &amp; Disease, 3(7):e359–e359, July 2012. URL: http://dx.doi.org/10.1038/cddis.2012.76, doi:10.1038/cddis.2012.76. This article has 71 citations.](https://doi.org/10.1038/cddis.2012.76)

[2. (Yu2021Function) Zongdong Yu, Jie Zhu, Haibiao Wang, Hong Li, and Xiaofeng Jin. Function of bclaf1 in human disease (review). Oncology Letters, December 2021. URL: http://dx.doi.org/10.3892/ol.2021.13176, doi:10.3892/ol.2021.13176. This article has 23 citations and is from a peer-reviewed journal.](https://doi.org/10.3892/ol.2021.13176)

[3. (Zhou2014BCLAF1) Xuexia Zhou, Xuebing Li, Yuanming Cheng, Wenwu Wu, Zhiqin Xie, Qiulei Xi, Jun Han, Guohao Wu, Jing Fang, and Ying Feng. Bclaf1 and its splicing regulator srsf10 regulate the tumorigenic potential of colon cancer cells. Nature Communications, August 2014. URL: http://dx.doi.org/10.1038/ncomms5581, doi:10.1038/ncomms5581. This article has 140 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/ncomms5581)

[4. (Yao2023BCLAF1induced) Bowen Yao, Ye Lu, Yazhao Li, Yixue Bai, Xinyu Wei, Yuanyuan Yang, and Demao Yao. Bclaf1-induced hif-1α accumulation under normoxia enhances pd-l1 treatment resistances via bclaf1-cul3 complex. Cancer Immunology, Immunotherapy, 72(12):4279–4292, October 2023. URL: http://dx.doi.org/10.1007/s00262-023-03563-8, doi:10.1007/s00262-023-03563-8. This article has 3 citations.](https://doi.org/10.1007/s00262-023-03563-8)

[5. (Qin2019Bclaf1) Chao Qin, Rui Zhang, Yue Lang, Anwen Shao, Aotian Xu, Wenhai Feng, Jun Han, Mengdong Wang, Wanwei He, Cuilian Yu, and Jun Tang. Bclaf1 critically regulates the type i interferon response and is degraded by alphaherpesvirus us3. PLOS Pathogens, 15(1):e1007559, January 2019. URL: http://dx.doi.org/10.1371/journal.ppat.1007559, doi:10.1371/journal.ppat.1007559. This article has 44 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1371/journal.ppat.1007559)

[6. (Sarras2010In) Haya Sarras, Solmaz Alizadeh Azami, and J. Peter McPherson. In search of a function for bclaf1. The Scientific World JOURNAL, 10:1450–1461, 2010. URL: http://dx.doi.org/10.1100/tsw.2010.132, doi:10.1100/tsw.2010.132. This article has 53 citations.](https://doi.org/10.1100/tsw.2010.132)

[7. (Dell’Aversana2017miR1945pBCLAF1) C Dell’Aversana, C Giorgio, L D’Amato, G Lania, F Matarese, S Saeed, A Di Costanzo, V Belsito Petrizzi, C Ingenito, J H A Martens, I Pallavicini, S Minucci, A Carissimo, H G Stunnenberg, and L Altucci. Mir-194-5p/bclaf1 deregulation in aml tumorigenesis. Leukemia, 31(11):2315–2325, February 2017. URL: http://dx.doi.org/10.1038/leu.2017.64, doi:10.1038/leu.2017.64. This article has 59 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/leu.2017.64)

[8. (McPherson2012BCLAF1) JP McPherson. Bclaf1 (bcl2-associated transcription factor 1). Atlas of Genetics and Cytogenetics in Oncology and Haematology, March 2012. URL: http://dx.doi.org/10.4267/2042/46079, doi:10.4267/2042/46079. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.4267/2042/46079)

[9. (Shao2016Bclaf1) A-w Shao, H Sun, Y Geng, Q Peng, P Wang, J Chen, T Xiong, R Cao, and J Tang. Bclaf1 is an important nf-κb signaling transducer and c/ebpβ regulator in dna damage-induced senescence. Cell Death &amp; Differentiation, 23(5):865–875, January 2016. URL: http://dx.doi.org/10.1038/cdd.2015.150, doi:10.1038/cdd.2015.150. This article has 58 citations.](https://doi.org/10.1038/cdd.2015.150)

[10. (Shcherbakova2021Identifying) Liudmila Shcherbakova, Mercedes Pardo, Theodoros Roumeliotis, and Jyoti Choudhary. Identifying and characterising thrap3, bclaf1 and erh interactions using cross-linking mass spectrometry. Wellcome Open Research, 6:260, October 2021. URL: http://dx.doi.org/10.12688/wellcomeopenres.17160.1, doi:10.12688/wellcomeopenres.17160.1. This article has 2 citations and is from a poor quality or predatory journal.](https://doi.org/10.12688/wellcomeopenres.17160.1)

[11. (Mou2020BCLAF1) Shao-Jiao Mou, Peng-Fei Yang, Yi-Pin Liu, Ning Xu, Wei-Wei Jiang, and Wen-Jing Yue. Bclaf1 promotes cell proliferation, invasion and drug-resistance though targeting lncrna neat1 in hepatocellular carcinoma. Life Sciences, 242:117177, February 2020. URL: http://dx.doi.org/10.1016/j.lfs.2019.117177, doi:10.1016/j.lfs.2019.117177. This article has 40 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.lfs.2019.117177)